background: Women with polycystic ovary syndrome (PCOS) are known to have high prevalence of acne and elevated androgen levels.
Introduction
Hyperandrogenism is one of the most important characteristics of women with polycystic ovary syndrome (PCOS). It has been reported that hyperandrogenism might lead to the polycystic ovary morphology and ovulatory dysfunction in animal models and in women with PCOS (Jonard and Dewailly, 2004; Chen et al., 2008) . Therefore, the androgen excess with either biochemical or phenotypic hyperandrogenism has been suggested as a necessary criterion for the diagnosis of PCOS . The main source of androgen in women with PCOS is the ovary (Barnes et al., 1989) , although 36-50% of women with PCOS have elevated adrenal androgens such as dehydroepiandrosterone sulfate (DHEAS; Carmina, 2006; Carmina and Lobo, 2007) . Ovarian and adrenal androgens have been reported to have opposing effects on body weight and insulin levels in women with PCOS (Buffington et al., 1991; Carmina and Lobo, 2007; Brennan et al., 2009 ) but the results are controversial. The androgen secreted from the ovary is mainly testosterone. Some studies have † These two authors had equal contribution to this study as the corresponding author.
reported that the concentrations of testosterone are higher in obese than non-obese women with PCOS (Acien et al., 1999; Moran et al., 2008) . Still other studies did not find such an association between obesity and high testosterone levels in women with PCOS (Kiddy et al., 1990; Silfen et al., 2003) . Furthermore, the testosterone level has been reported to be inversely related to abdominal obesity and metabolic syndrome in men (Kupelian et al., 2008) .
The DHEAS level, unlike the testosterone level, is comparable in men and women, and has been reported to be related to the presence of acne (Slayden et al., 2001; Cappel et al., 2005) . Furthermore, the serum DHEAS level has been reported to be even higher in women than men of a similar age, BMI and insulin level (Jakubowicz et al., 1995) . Significantly, increased serum levels of DHEAS were found after weight reduction by diet control in obese men (Jakubowicz et al., 1995) and by laparoscopic gastric banding surgery in morbidly obese women (Savastano et al., 2005) . In addition, a higher circulating DHEAS level has been reported to correlate with favorable metabolic parameters including better lipid profiles, lower body weight, higher insulin sensitivity index and decreased vascular dysfunction (Buffington et al., 1991; Moran et al., 1999; Meyer et al., 2005; Carmina and Lobo, 2007; Brennan et al., 2009 ) both in men and women. In contrast, other studies suggest a positive relationship between DHEAS and the increased risk of metabolic disturbances, such as hypertension and hepatic steatosis, both in men and women (Schunkert et al., 1999; Volzke et al., 2010) .
Collectively, the effects of both testosterone and DHEAS on metabolic disturbances and obesity are still unclear. A high level of circulating DHEAS may naturally be converted to testosterone and then to estrogen under normal physiologic conditions, and is always associated with high circulating testosterone levels, especially in women (Allolio and Arlt, 2002; Piltonen et al., 2002; Roberge et al., 2007) . Most of the above-mentioned studies did not consider the interactive confounding effect between testosterone and DHEAS. Therefore, in the present study, we aimed to determine the effect of DHEAS and abdominal obesity in women with PCOS after further consideration of the accompanying high testosterone levels and other confounding factors, such as advanced age, insulin resistance (IR) and dyslipidemia. The effects of androgens and obesity on phenotypic acne of women with PCOS were also investigated.
Materials and Methods

Subjects and data collection
A total of 318 consecutive women with PCOS were enrolled in this study. All of the women were recruited from our reproductive endocrinology clinic with a chief complaint of irregular menstrual cycles and/or clinical hyperandrogenism; none of the women had been prescribed any medications before enrollment. The study protocol was approved by the Institutional Review Board of the National Taiwan University Hospital. Written informed consent was obtained from all of the subjects and/or their parents or legal guardian before participation in the study. The diagnosis of PCOS was based on the Rotterdam criteria (The Rotterdam ESHRE/ ASRM-Sponsored PCOS consensus working group, 2004) , in which at least two of the following three criteria were met: (i) oligomenorrhea (,8 spontaneous menstrual cycles per year for at least 3 years before enrollment) or amenorrhea; (ii) biochemical hyperandrogenemia (serum total testosterone level ≥2.78 nmol/l) and (iii) polycystic ovaries [.12 follicles of 2 -9-mm diameter per ovary by transvaginal ultrasonography or an ovarian volume .10 ml per ovary by transabdominal ultrasonography with a distended bladder (for virginal women)]. Phenotypic hirsutism was defined as a Ferriman -Gallwey score .8 and clinical acne was defined by a history of persistent acne (acne presents on most days for at least 3 years), recent acne treatment and the presence of more than 10 inflammatory acne lesions (Cappel et al., 2005) . However, because the diagnosis of phenotypic hyperandrogenism is based on a variety of definitions in different studies (Goulden et al., 1999; Slayden et al., 2001; Cappel et al., 2005) , neither hirsutism nor acne were used as diagnostic criteria for subject enrollment.
In addition, the diagnosis of PCOS was only made after excluding hyperprolactinemia, thyroid dysfunction, Cushing's syndrome, congenital adrenal hyperplasia, an adrenal tumor, an ovarian tumor, current pregnancy or previous pregnancy within 1 year of enrollment (to avoid the temporary physiological anovulation after breastfeeding, that might confound diagnosis of PCOS), autoimmune disease, malignancy, central nervous system disease, current or previous use of oral contraceptives within 6 months of enrollment or the use of medications known to affect the hypothalamicpituitary-ovarian axis, such as anti-androgens, ovulation induction agents, antidiabetic medications, antiobesity medications or glucocorticoids.
After overnight fasting, blood samples were collected from PCOS subjects with amenorrhea exceeding 3 months without hormone-induced withdrawal bleeding, and in the early follicular phase for those women who ovulated spontaneously. The process for blood sampling and collection in women with PCOS has been described in detail in our previous studies (Chen et al., 2006 (Chen et al., , 2007 (Chen et al., , 2008 . All blood samples were processed to obtain both serum and plasma, within 30 min of collection. Blood glucose and insulin levels were determined on the day of sampling, then the remaining serum and plasma were aliquoted and frozen at 2708C.
The chosen cut-off value for waist circumference at 80 cm is based on the modified criteria of metabolic syndrome from the National Cholesterol Education Program-Adult Treatment Panel III, used for assessing abdominal obesity in Asian women (Tan et al., 2004) . The other cut-off value we used in the present study to define abdominal obesity was 0.8 for the waist-to-hip ratio, according to previous studies (Van Gaal et al., 1989; Zaadstra et al., 1993) . Obesity was defined as a BMI ≥ 25 kg/m 2 based on the guidelines for the adult Asian population (WHO Expert Consultation, 2004) . The threshold for elevated DHEAS levels was defined by the highest quartile of DHEAS level in the present study, which was ≥6.68 mmol/l.
Laboratory assays
The concentration of plasma glucose was measured with an autoanalyzer (Toshiba TBA-120 FR; Toshiba, Tokyo, Japan). The serum levels of total cholesterol, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) and triglycerides were measured with a biochemical autoanalyzer (Toshiba TBA-200FR; Toshiba). Serum insulin levels were determined by a microparticle enzyme immunoassay using an AxSYM system (Abbott Laboratories, Dainabot Co., Tokyo, Japan). Serum FSH, LH, estradiol (E 2 ) and progesterone levels were measured by indirect chemiluminescence (Vitros Eci; Ortho-Clinical Diagnostics, Rochester, NY, USA). Serum sex hormone-binding globulin (SHBG) was measured by electrochemiluminescence (Elecsys 2010; Roche Diagnostics, Indianapolis, IN, USA). Serum total testosterone and DHEAS levels were measured by radioimmunoassay (Diagnostic Systems Laboratories, Webster, TX, USA). The homeostasis model assessment (HOMA) and free androgen index (FAI) were applied to estimate the degree of IR and bioavailable testosterone, respectively. HOMA of IR (HOMA-IR) and FAI were calculated as described previously (Chen et al., 2007) . All samples were measured in the same assay. Samples were analyzed in duplicate and in random order so as to reduce possible processing bias. The mean of the duplicates was used for analysis. The intra-and interassay coefficients of variation (as provided by the manufacturer) of the aforementioned assays were all ,10%.
Statistical analysis
The numerical variables are expressed as the mean + SD, unless indicated otherwise. All variables were tested by the Shapiro-Wilk W-test to identify whether or not the variables were normally distributed before further analyses. Spearman rank's correlation coefficients were calculated to determine the correlations between DHEAS, total testosterone and other anthropometric, hormonal and metabolic variables. The MannWhitney U-test and Student's t-test were used as appropriate for comparison of two groups. For comparisons of variables between four groups of DHEAS quartiles, the Kruskall -Wallis test for continuous variables and Fisher's exact test for proportional variables were performed where appropriate. The risk of phenotypic acne, hirsutism and abdominal obesity in association with the DHEAS quartiles in women with PCOS was compared using the two-sided Cochran-Armitage trend test and proportional logistic regression analyses for further multiple variables adjustment, when appropriate. Multivariate logistic regression analyses with dummy DHEAS quartile variables were used to assess the association between abdominal obesity and the severity of adrenal androgen excess after adjustment for age, HOMA-IR, total testosterone, E 2 and lipid profiles: to avoid the effects of collinearity, we used HOMA-IR instead of fasting glucose and insulin, and used triglycerides and LDL-C instead of total cholesterol in the final models. A P , 0.05 was considered statistically significant. All of the statistical analyses were performed using the PC version of the Statistical Analysis System (SAS version 9.1: SAS Institute Inc., Cary, NC, USA).
Results
Among the 318 consecutive women with PCOS enrolled in this study, 209 (65.7%) exhibited biochemical hyperandrogenemia with a total testosterone ≥2.78 nmol/l. Women with PCOS and an elevated total testosterone level not only had a concurrent higher level of DHEAS, but also had an increased waist circumference, BMI and IR than those women without elevated total testosterone levels ( Table I) . As expected, in all women, irrespective of total testosterone level, all metabolism-related measurements, including waist circumference, waist-to-hip ratio, FAI, fasting glucose, insulin, HOMA-IR, LDL-C and triglycerides were significantly higher in obese than non-obese women with PCOS. In contrast, the SHBG, LH and HDL-C levels were significantly lower in obese than non-obese women with PCOS (Table I) . Even though the DHEAS levels were higher in women with, than without, elevated total testosterone levels in both obese and non-obese women with PCOS, the DHEAS levels were significantly lower in obese than non-obese PCOS women and irrespective of total testosterone level ( Table I) . The demographic characteristics of the 318 women, including anthropometric measurements, hormonal profiles and lipid profiles, together with unadjusted correlation analyses are presented in Table II . DHEAS was positively correlated to the total testosterone and FAI levels, but negatively related to the age, waist circumference, waist-to-hip ratio, BMI, LDL-C and triglycerides. In contrast, total testosterone was negatively correlated to age, SHBG and HDL-C levels, but positively correlated to DHEAS, waist circumference, waist-to-hip ratio, BMI, FAI, LH, E 2 , insulin, HOMA-IR, LDL-C and triglycerides (Table II) . After further adjusting for confounding effects of age and total testosterone level, the DHEAS level was still significantly negatively correlated to the BMI, waist circumference, waist-to-hip ratio, BMI, LDL-C and triglycerides in women with PCOS (data not shown).
Of the 318 women with PCOS, 123 (38.7%) exhibited phenotypic acne and 117 (36.8%) had hirsutism. Women with acne were significantly younger (P , 0.0001), had higher DHEAS levels (P ¼ 0.002) and a lower BMI (P ¼ 0.0006) than women without acne, while the total testosterone levels did not differ between women with and without acne (Table III) . Age, BMI, DHEAS and total testosterone levels were not significantly different among women with and without phenotypic hirsutism (data not shown). Women with higher DHEAS levels also tended to have a higher prevalence of phenotypic acne (Table IV) . In addition, the elevated DHEAS level (using the cut-off value of 6.68 mmol/l: the highest quartile of DHEAS level in this study) was also noted to increase the risk of phenotypic acne [odds ratio (OR) ¼ 2.15, 95% confidence interval (CI): 1.25 -3.68, P ¼ 0.005] after further adjustment for age and BMI in multivariate logistic regression analysis (data not shown).
To further investigate, the inverse relationship between DHEAS and abdominal obesity in women with PCOS, we then analyzed the association of waist circumference and waist-to-hip ratio and DHEAS level by the quartile of DHEAS levels and by adjustment for age, IR, hormonal profile and metabolic factors. The results are summarized in Table IV . The risk of abdominal obesity tended to be lower among women with PCOS with higher DHEAS level. Such a negative association between abdominal obesity and DHEAS levels persisted after adjustment for age, total testosterone, HOMA-IR, E 2 and lipid profile. Women with PCOS who had the highest quartile of DHEAS level had the lowest risk of abdominal obesity (OR ¼ 0.26, 95% CI: 0.10 -0.64, for a waist circumference cut-off of 80 cm; OR ¼ 0.22, 95% CI: 0.10 -0.51, for waist-to-hip ratio cut-off of 0.8) after the adjustment for age, ovarian hyperandrogenemia, IR and dyslipidemia.
Discussion
The present study showed that the high serum DHEAS level in women with PCOS was associated with the presence of acne and a reduced risk of abdominal obesity, independent of serum testosterone concentration and IR. Dehydroepiandrosterone (DHEA) and its sulfate ester, DHEAS are major secretory products of the human adrenal cortex (Allolio and Arlt, 2002) and physiologically, DHEA and DHEAS may undergo continuous interconversion (Bird et al., 1984) and also convert to other androgens, such as androstenedione and testosterone, in the peripheral target tissues. Although the gonads are the major sources of testosterone in men and women, circulating testosterone also comes from the conversion of adrenal androgens, especially in women of reproductive age whose ovaries only contribute 25-30% of the circulating testosterone, and in post-menopausal women whose adrenal glands are virtually the exclusive source of circulating testosterone (Couzinet et al., 2001; Piltonen et al., 2002; Roberge et al., 2007) . Therefore, the high adrenal androgen levels may always be accompanied by elevated gonadal androgen levels, as also shown in this study. DHEAS has been reported to oppose testosterone with respect to the risk of obesity, IR and metabolic disturbances, although this is controversial for women with hyperandrogenism and PCOS (Buffington et al., 1991; Carmina and Lobo, 2007; Brennan et al., 2009) . We hypothesized that such controversy for the relationship between DHEAS, obesity and other metabolic disturbances might reflect a lack of consideration of the interactive confounding effect from testosterone in most of the studies (Buffington et al., 1991; Jakubowicz et al., 1995; Moran et al., 1999; Schunkert et al., 1999; Carmina and Lobo, 2007; Brennan et al., 2009) .
In this study, as expected, we showed that the DHEAS levels were positively correlated with the total testosterone levels in women with PCOS, and lower DHEAS concentrations existed in obese women than non-obese women with and without elevated testosterone levels. In addition, the inverse relationship between DHEAS and indices of abdominal obesity, such as waist circumference and waist-to-hip ratio was evident in women with and without elevated total testosterone levels. Furthermore, by using multivariate regression analysis, the inverse relationship between DHEAS and abdominal obesity was still significant after further adjustment for the concurrent high testosterone level, advanced age, IR and dyslipidemia. All of the above findings were consistent with our previous hypothesis that high DHEAS levels were related to the more favorable outcomes of the metabolic disturbance and abdominal obesity after considering the interactive confounding effect of testosterone.
Little is known about the mechanism by which DHEAS reduces the risk of abdominal obesity. Though previous studies had found the concentration of DHEAS may increase after weight loss (Jakubowicz et al., 1995; Savastano et al., 2005) and a decrease in serum DHEAS levels over time is associated with the development of diabetes (Kameda et al., 2005) , the above-mentioned findings suggest a possible protective effect of the endogenous DHEAS on obesity, IR and metabolic disturbances. In animal studies (rats), it has been reported that exogenous DHEA administration may lead to a significant reduction in food intake, body weight, total body fat content, the weight of different adipose depots and adipocyte size (de Heredia et al., 2007) . In addition, DHEA-treated rats have a significantly lower serum insulin concentration and tended to have a lower HOMA-IR (Sanchez et al., 2008) . However, in human studies, exogenous DHEA treatment did not change body composition, insulin sensitivity and metabolic profiles, except decreased HDL-C, in either men or women of advanced age (Morales et al., 1994) or reproductive-aged women with adrenal insufficiency (Allolio and Arlt, 2002; Christiansen et al., 2005) . Nevertheless, the beneficial effect of DHEAS on abdominal obesity and metabolic disturbances that was not highlighted in the intervention studies might be secondary to the accompanying anabolic effect of the concurrent elevated testosterone concentration. The low DHEAS level found in obese women with PCOS might also result from the obesity itself, as one study reported that hyperinsulinemia can increase the metabolic clearance rate of DHEA in men (Lavallee et al., 1997) . However, the current study is only a cross-sectional observation study, therefore, we cannot determine if the high DHEAS led to the low abdominal obesity, or on the other hand, the obesity and metabolic disturbances affected the levels of DHEAS. We do find that the inverse relationship between DHEAS and abdominal obesity still exists after considering the concurrent high total testosterone level in women with PCOS.
Asian populations, such as Japanese and Chinese are known to have a lower prevalence and severity of hirsutism and obesity than Caucasians (Lookingbill et al., 1991; WHO Expert Consultation, 2004) , which might result from genetic and environmental differences. Unlike hirsutism, acne is one of the phenotypic characteristics of hyperandrogenism, but is still controversial when used as a criterion for the diagnosis of PCOS. A previous study involving a Taiwanese population reported that obese women with PCOS have a lower prevalence of acne than non-obese women with PCOS; however, the reason for such an inverse relationship between obesity and acne is unknown (Liou et al., 2009) . In our study, we showed that women with acne were younger, less obese and had higher DHEAS levels than women without phenotypic acne. The association between DHEAS and acne still exists after adjusting for age and BMI. Previous studies (Slayden et al., 2001; Cappel et al., 2005) had also reported that the presence of acne is related to high circulating DHEAS levels, but not the total testosterone level, as also shown in the current study. According to our findings, we may conclude that the lower prevalence of acne in obese women with PCOS might be related to lower DHEAS concentrations in women with obesity. However, although some subjects did undergo quanitification of their acne by lesion count, the diagnosis of phenotypic acne was not made by a single observer therefore data for a dose -response relationship between DHEAS level and severity of acne are not available here. Therefore, it is reasonable for us to speculate that the differential phenotypes of women with PCOS between various studies and ethnicities might partially be linked to the differential ratio of adrenal and ovarian androgens. Such differences might be a result of genetic or environmental influences; however, further studies are needed to verify such speculation.
There were several limitations of the present study. Based on different criteria for the severity of acne in previous studies, the prevalence of acne among the adult population varied from 12 to 54% (Goulden et al., 1999) and was not always related to disturbed metabolic and hormonal profiles (Ozdemir et al., 2010) . Though we showed that the women with PCOS and acne have higher DHEAS levels than women with PCOS and no acne, we could not determine whether the actual prevalence of acne was specifically increased in women with PCOS compared with the normal population as no control subjects were included in this study. In addition, data regarding the other confounding factors which are related to the presence of acne, such as history of sun exposure time, presence of stress, baseline skin type and nutritional status of the study subjects, were not available in the current study. Furthermore, the chosen criteria for hyperandrogenism were only confined to total testosterone ≥2.78 nmol/l and no oral contraceptive use in the previous 6 months, therefore only the more severely affected study subjects might be included in the study. All of the above-mentioned limitations may restrict the applicability of results to the present study, and cannot be applied to women with PCOS in general.
In conclusion, our study demonstrated that DHEAS and total testosterone have different relationships with body weight, abdominal obesity and dyslipidemia in women with PCOS. High DHEAS levels in PCOS women were associated with a significantly reduced risk of abdominal obesity, independent of the serum total testosterone concentration and IR. The inverse relationship between obesity and acne in women with PCOS can be partially explained by the negative association between serum DHEAS concentration and obesity, regardless of age and testosterone level.
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